Tumour burden and antigen-specific T cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T cell therapy
Marion Mallet, Rasha Boulos, Vincent Alcazer, Paola Bonaventura, Yann Estornes, Nicolas Chuvin, Stéphane Depil
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.